Serena Vilasi

Ms. Serena Vilasi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SVSerena Vilasi
Serena Vilasi
JNJannett Nguyen
Jannett Nguyen
CWCatherine J. Wang
Catherine J. Wang
LMLingling Miao
Lingling Miao
KDKenneth Daily
Kenneth Daily
IBIsaac Brownell
Isaac Brownell
Merkel cell carcinoma (MCC) and small cell lung cancer (SCLC) can be histologically similar. Immunohistochemistry (IHC) for cytokeratin 20 (CK20) and thyroid transcription factor 1 (TTF-1) are commonly used to differentiate MCC from SCLC; however, these markers have limited sensitivity and specificity. To identify new diagnostic markers, we performed differential gene expression analysis on transcriptome data from MCC and SCLC tumors. Candidate markers included atonal BHLH transcription factor 1 (ATOH1) and transcription factor AP-2β (TFAP2B) for MCC, as well as carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) for SCLC. Immunostaining for CK20, TTF-1, and new candidate markers was performed on 43 MCC and 59 SCLC samples. All three MCC markers were sensitive and specific, with CK20 and ATOH1 staining 43/43 (100%) MCC and 0/59 (0%) SCLC cases and TFAP2B staining 40/43 (93%) MCC and 0/59 (0%) SCLC cases. TTF-1 stained 47/59 (80%) SCLC and 1/43 (2%) MCC cases. CEACAM6 stained 49/59 (83%) SCLC and 0/43 (0%) MCC cases. Combining CEACAM6 and TTF-1 increased SCLC detection sensitivity to 93% and specificity to 98%. These data suggest that ATOH1, TFAP2B, and CEACAM6 should be explored as markers to differentiate MCC and SCLC.

21 November 2022 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
MMMackenzie R. Martin
Mackenzie R. Martin
NMNoreen Mohsin
Noreen Mohsin
SVSerena Vilasi
Serena Vilasi
DRDanielle Reed
Danielle Reed
IBIsaac Brownell
Isaac Brownell
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer that predominantly impacts White patients. Overall incidence and the proportion of minority patients with MCC are both rising. In the more common skin cancer, melanoma, racial disparities are well-documented in stage at presentation and patient survival. Whether racial and ethnic disparities exist in MCC remains unclear. The study of MCC disparities is hampered by limitations in data registries, including SEER and NCDB, and an evolving natural history due to the advent of immunotherapy. Published MCC immunotherapy clinical trials consistently reported the racial diversity among enrolled subjects but failed to include patients’ ethnicities. Efforts to improve data capture in cancer registries and create multi-institutional clinical databases will allow for more effective study of racial and ethnic disparities in rare cancers like MCC. Such studies are needed to advance policies promoting equity in care.

24 February 2024 in JAAD Case Reports
Verified
Journal Article
Open access
SVSerena Vilasi
Serena Vilasi
LLLydia A. Luu
Lydia A. Luu
MNMary M.B. Noland
Mary M.B. Noland

16 February 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
SVSerena Vilasi
Serena Vilasi
CSCraig Slingluff
Craig Slingluff
Objectives: Little is known about the impact of patient age and biological sex on immune responses to melanoma vaccines, especially CD4+ T cell immune responses to peptides presented by Class II MHC molecules. Methods: We assessed the impact of age and sex on CD4+ T cell and antibody responses to a mixture of six melanoma helper peptides (6MHP) and on CD8+ T cell responses when vaccinating with 12 class I MHC-restricted melanoma peptides (12MP) plus either 6MHP or a tetanus helper T cell peptide (Tet). We hypothesized that immune responses would be greater in men and in younger patients. Results: We found differences in immune response by sex, but they favored female patients and were only evident for helper T cell responses to Tet with a weak trend to higher T cell responses to 12MP in female patients vaccinated with 12MP + Tet. The age-based differences favored younger patients but only for immune response to 12MP when inoculated with 12MP + Tet. Conclusions: These findings reinforce the importance of assessing sex- and age-based differences in immune responses to cancer vaccines and other immune therapies. There is also a need to understand the reasons for such differences.

1 January 2023 in Journal of Cutaneous Oncology
Verified
Journal Article
Open access
SVSerena Vilasi
Serena Vilasi
DMDavid M. Miller
David M. Miller
MHMassachusetts General Hospital
Massachusetts General Hospital
HKHoward Kaufman
Howard Kaufman
KEKevin S. Emerick
Kevin S. Emerick
IBIsaac Brownell
Isaac Brownell
In this Perspectives on the Science piece we reflect on the impact of the recently published SWOG S1801 trial.